<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="1623" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="864" end="867"/>
    <type:PFSMean xmi:id="17" sofa="6" begin="972" end="983"/>
    <type:PFSTime xmi:id="21" sofa="6" begin="1067" end="1075"/>
    <type:OSTime xmi:id="25" sofa="6" begin="1084" end="1088"/>
    <type:PFSRate xmi:id="29" sofa="6" begin="1117" end="1122"/>
    <type:OSRate xmi:id="33" sofa="6" begin="1147" end="1152"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="Although cladribine has been reported to be an active purine analog against&#13;&#10;indolent B-cell non-Hodgkin lymphoma (B-NHL), there are few reports of&#13;&#10;combination use of cladribine and rituximab. This multicenter phase II study&#13;&#10;evaluated the efficacy and toxicity of cladribine with rituximab (R-2-CdA)&#13;&#10;therapy in relapsed or refractory indolent B-NHL. Twenty patients with the median&#13;&#10;age of 58.5 yrs (range, 42-72) were enrolled and received R-2-CdA therapy from&#13;&#10;April 2005 to July 2007. The median number of prior regimens was 2 (range, 1-3), &#13;&#10;and fifteen patients (75%) were previously treated with rituximab-containing&#13;&#10;regimens. Disease histology included follicular lymphoma in 16 patients, MALT&#13;&#10;lymphoma in two patients, nodal marginal B-cell lymphoma in one patient, and&#13;&#10;lymphoplasmacytic lymphoma in one patient. The overall response rate (ORR) was&#13;&#10;90%, with a complete response rate (CRR) of 70%. Estimated median&#13;&#10;progression-free survival (PFS) time was 22.4 months (95%CI, 10.9-32.6 months) at&#13;&#10;a median follow-up time of 27 months (range, 12-43). Two-year PFS and 2-yr&#13;&#10;overall survival (OS) were 52.6% (95%CI, 31.0-73.2%) and 89.5% (95%CI,&#13;&#10;66.1-97.3%), respectively. Grade 3 or grade 4 toxicities were neutropenia in 74% &#13;&#10;and thrombocytopenia in 11%. R-2-CdA therapy was demonstrated to have a high&#13;&#10;activity with durable PFS and acceptable toxicity in relapsed or refractory&#13;&#10;indolent B-NHL mostly pretreated with rituximab-containing therapy. Although a&#13;&#10;large-scale trial is needed for confirmation, R-2-CdA therapy could be a good&#13;&#10;salvage therapy option in relapsed or refractory indolent B-NHL."/>
    <cas:View sofa="6" members="1 13 17 21 25 29 33"/>
</xmi:XMI>
